KCTD8 antibody (AA 381-473) (HRP)

Catalog No. ABIN1412978

Product Details anti-KCTD8 Antibody (HRP)

Target: KCTD8 (Potassium Channel Tetramerisation Domain Containing 8 (KCTD8))

Binding Specificity: AA 381-473

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This KCTD8 antibody is conjugated to HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Cross-Reactivity: Human, Mouse

Predicted Reactivity: Rat,Dog,Cow,Sheep,Pig,Horse,Chicken,Rabbit

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human KCTD8

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for KCTD8

Target: KCTD8 (Potassium Channel Tetramerisation Domain Containing 8 (KCTD8))

Alternative Name: KCTD8 (KCTD8 Products)

Synonyms: A730087N02Rik antibody, potassium channel tetramerisation domain containing 8 antibody, potassium channel tetramerization domain containing 8 antibody, Kctd8 antibody, KCTD8 antibody

Background:

Synonyms: BTB/POZ domain-containing protein KCTD8, KCTD8, KCTD8_HUMAN, Potassium channel tetramerisation domain containing 8.

Background: Auxiliary subunit of GABA-B receptors that determine the pharmacology and kinetics of the receptor response. Increases agonist potency and markedly alter the G-protein signaling of the receptors by accelerating onset and promoting desensitization.

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling